Rock Springs Capital Management LP Amylyx Pharmaceuticals, Inc. Transaction History

Rock Springs Capital Management LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$2.71 - $19.57 $1.29 Million - $9.32 Million	476,400 Added 89.04%	1,011,412 $2.87 Million
Q4 2023 Feb 14, 2024	SELL	$12.07 - $18.46 $12.2 Million - $18.6 Million	-1,010,004 Reduced 65.37%	535,012 $7.88 Million
Q3 2023 Nov 14, 2023	BUY	$18.08 - $23.45 $7,231 - $9,380	400 Added 0.03%	1,545,016 $28.3 Million
Q2 2023 Aug 14, 2023	BUY	$20.98 - $31.42 $1.93 Million - $2.88 Million	91,800 Added 6.32%	1,544,616 $33.3 Million
Q1 2023 May 15, 2023	BUY	$27.71 - $40.93 $6.18 Million - $9.13 Million	223,179 Added 18.15%	1,452,816 $42.6 Million
Q4 2022 Feb 14, 2023	BUY	$29.75 - $39.26 $24.6 Million - $32.4 Million	825,900 Added 204.56%	1,229,637 $45.4 Million
Q3 2022 Nov 14, 2022	SELL	$17.15 - $30.92 $9.78 Million - $17.6 Million	-570,370 Reduced 58.55%	403,737 $11.4 Million
Q2 2022 Aug 15, 2022	SELL	$6.85 - $19.93 $165,770 - $482,306	-24,200 Reduced 2.42%	974,107 $18.8 Million
Q1 2022 May 16, 2022	BUY	$12.85 - $32.9 $12.8 Million - $32.8 Million	998,307 New	998,307 $12.8 Million

127

44.4M

235K

530K

Ticker AMLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,533,200
Market Cap $227M
Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.